FDA rejects Zealand Pharma application due to problems at contract manufacturer
The FDA has not expressed any concerns regarding the clinical data package or the safety of the drug.
Zealand Pharma’s registration application for dasiglucagon, a drug for the prevention and treatment of congenital hypoglycemia in infants and children, has been rejected by the US health authorities due to problems with its third-party manufacturing.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
